We are talking again about prostate cancer. We are at the beginning of our journey with men getting screened for prostate cancer using PSA testing and other validated measures to determine if a prostate biopsy should be performed.

For the purposes of this episode, I am going to be referring to the current AUA guidelines on Early Detection of Prostate Cancer updated in 2023. I covered the first 7 guidelines in the last episode. This episode will cover guidelines 8-11. Reference: https://www.auanet.org/guidelines-and-quality/guidelines/early-detection-of-prostate-cancer-guidelines#x18448

Guideline 8: “Clinicians may use digital rectal exam (DRE) alongside PSA to establish risk of clinically significant prostate cancer.”

Guideline 9: "for men undergoing prostate cancer screening, clinicians should not use PSA velocity as the sole indication for a secondary biomarker, imaging, or biopsy."

Guideline 10: “Clinicians and patients may use validated risk calculators to inform the SDM process regarding prostate biopsy.”

Guidleline 11: “When the risk of clinically significant prostate cancer is sufficiently low based on available clinical, laboratory, and imaging data, clinicians and patients may forgo near-term prostate biopsy.”

LINKS to Shared Decision Making Tools

https://www.prostatecancer-riskcalculator.com

https://riskcalc.org